Table 3 Pathways enriched in the transcriptome of peritoneal effluent cells obtained from PET tests in the randomized trial with and without AlaGln.
Canonical Pathway | p-Value | Moleculesa |
|---|---|---|
Hepatic Fibrosis/Hepatic Stellate Cell Activation | 4,68E-06 | COL5A3↑, CTGF↑, COL6A3↑, CCL2↓, IL1RL1↑, PDGFRA↑, SERPINE1↑, TNF↓, PDGFRB↑ |
Noradrenaline and Adrenaline Degradation | 1,58E-04 | MAOB↑, ALDH1A1↑, DHRS9↓, ADH1B↑ |
Retinoate Biosynthesis I | 1,58E-03 | ALDH1A1↑, DHRS9↓, BMP2↑ |
Serotonin Degradation | 1,66E-03 | MAOB↑, ALDH1A1↑, DHRS9↓, ADH1B↑ |
Ethanol Degradation II | 2,04E-03 | ALDH1A1↑, DHRS9↓, ADH1B↑ |
Human Embryonic Stem Cell Pluripotency | 3,02E-03 | FZD8↑, IRS1↑, BMP2↑, PDGFRA↑, PDGFRB↑ |
Axonal Guidance Signaling | 3,72E-03 | FZD8↑, SEMA6D↑, GLI3↑, SEMA3D↑, ADAMTS1↑, IRS1↑, BMP2↑, NFATC2↑, ADAMTS9↑ |
PPAR Signaling | 3,80E-03 | IL1RL1↑, PDGFRA↑, TNF↓, PDGFRB↑ |
PAK Signaling | 5,13E-03 | IRS1↑, PDGFRA↑, TNF↓, PDGFRB↑ |
Role of Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid Arthritis | 5,25E-03 | FZD8↑, IL1RL1↑, IRS1↑, BMP2↑, NFATC2↑, TNF↓ |
Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis | 5,37E-03 | FZD8↑, CCL2↓, IL1RL1↑, IRS1↑, NFATC2↑, TNF↓, FCGR3A/FCGR3B |
Differential Regulation of Cytokine Production in Macrophages and T Helper Cells by IL-17A and IL-17F | 6,61E-03 | CCL2↓, TNF↓ |
MSP-RON Signaling Pathway | 7,59E-03 | CCL2↓, IRS1↑, TNF↓ |
NF-κB Signaling | 7,94E-03 | IRS1↑, BMP2↑, PDGFRA↑, TNF↓, PDGFRB↑ |
3-phosphoinositide Biosynthesis | 9,12E-03 | PTPN13↑, IRS1↑, PDGFRA↑, CILP↑, PDGFRB↑ |
Dendritic Cell Maturation | 9,77E-03 | COL5A3↑, DDR2↑, IRS1↑, TNF↓, FCGR3A/FCGR3B |
PXR/RXR Activation | 1,00E-02 | ALDH1A1↑, IGFBP1↑, TNF↓ |
Differential Regulation of Cytokine Production in Intestinal Epithelial Cells by IL-17A and IL-17F | 1,07E-02 | CCL2↓, TNF↓ |
Putrescine Degradation III | 1,07E-02 | MAOB↑, ALDH1A1↑ |
Atherosclerosis Signaling | 1,12E-02 | ALOX15↑, COL5A3↑, CCL2↓, TNF↓ |
IL-6 Signaling | 1,12E-02 | TNFAIP6↑, IL1RL1↑, IRS1↑, TNF↓ |
Tryptophan Degradation X (Mammalian, via Tryptamine) | 1,26E-02 | MAOB↑, ALDH1A1↑ |
HMGB1 Signaling | 1,32E-02 | CCL2↓, IRS1↑, SERPINE1↑, TNF↓ |
Basal Cell Carcinoma Signaling | 1,32E-02 | FZD8↑, GLI3↑, BMP2↑ |
TREM1 Signaling | 1,48E-02 | CCL2↓, IL1RL1↑, TNF↓ |
VDR/RXR Activation | 1,62E-02 | WT1↑, IL1RL1↑, IGFBP1↑ |
Superpathway of Inositol Phosphate Compounds | 1,95E-02 | PTPN13↑, IRS1↑, PDGFRA↑, CILP↑, PDGFRB↑ |
Glioblastoma Multiforme Signaling | 2,34E-02 | FZD8↑, IRS1↑, PDGFRA↑, PDGFRB↑ |
PDGF Signaling | 2,40E-02 | IRS1↑, PDGFRA↑, PDGFRB↑ |
Dopamine Degradation | 2,40E-02 | MAOB↑, ALDH1A1↑ |
Gαq Signaling | 2,40E-02 | IRS1↑, RGS16↑, RGS4↑, NFATC2↑ |
Granulocyte Adhesion and Diapedesis | 3,31E-02 | CCL2↓, JAM3↑, IL1RL1↑, TNF↓ |
Role of Hypercytokinemia/hyperchemokinemia in the Pathogenesis of Influenza | 3,47E-02 | CCL2↓, TNF↓ |
IGF-1 Signaling | 3,63E-02 | CTGF↑, IRS1↑, IGFBP1↑ |
IL-9 Signaling | 3,80E-02 | IRS1↑, TNF↓ |
G-Protein Coupled Receptor Signaling | 3,80E-02 | PTGER3↑, IRS1↑, RGS16↑, RGS4↑, PDE4D↑ |
Glioma Signaling | 3,98E-02 | IRS1↑, PDGFRA↑, PDGFRB↑ |
p53 Signaling | 4,07E-02 | WT1↑, THBS1↑, IRS1↑ |
Agranulocyte Adhesion and Diapedesis | 4,07E-02 | CCL2↓, JAM3↑, CD34↑, TNF↓ |
Regulation of the Epithelial-Mesenchymal Transition Pathway | 4,07E-02 | FZD8↑, IRS1↑, JAG1↑, PDGFRB↑ |
Glucocorticoid Receptor Signaling | 4,68E-02 | CCL2↓, IRS1↑, NFATC2↑, SERPINE1↑, TNF↓ |
Renin-Angiotensin Signaling | 4,90E-02 | CCL2↓, IRS1↑, TNF↓ |
Docosahexaenoic Acid (DHA) Signaling | 4,90E-02 | ALOX15↑, IRS1↑ |
LXR/RXR Activation | 5,01E-02 | CCL2↓, IL1RL1↑, TNF↓ |
